Copyright
©The Author(s) 2016.
World J Gastroenterol. May 21, 2016; 22(19): 4766-4775
Published online May 21, 2016. doi: 10.3748/wjg.v22.i19.4766
Published online May 21, 2016. doi: 10.3748/wjg.v22.i19.4766
Table 2 Summary of meta-analyses: hybrid therapy vs sequential and concomitant therapy
| Outcomes | Studies, n | Hybrid group | Control group | RR (95%CI) | I2 | P value for heterogeneity |
| Hybrid vs sequential | ||||||
| Eradication rate (PP) | 6 | 88.6% | 87.8% | 1.03 (0.94-1.12) | 82.2% | < 0.05 |
| Eradication rate (ITT) | 6 | 84.3% | 85.1% | 1.00 (0.89-1.12) | 85.2% | < 0.05 |
| Compliance rate | 5 | 96.0% | 98.0% | 0.99 (0.96-1.02) | 50.4% | > 0.05 |
| Side effect rate | 6 | 30.3% | 28.2% | 1.05 (0.86-1.02) | 37.8% | > 0.05 |
| Hybrid vs concomitant | ||||||
| Eradication rate (PP) | 5 | 91.3% | 92.4% | 1.01 (0.96-1.05) | 56.1% | < 0.05 |
| Eradication rate (ITT) | 5 | 84.8% | 86.7% | 0.99 (0.95-1.03) | 0 | > 0.05 |
| Compliance rate | 4 | 95.8% | 93.2% | 1.03 (1.00-1.05) 1 | 0 | > 0.05 |
| Side effect rate | 4 | 39.5% | 44.2% | 0.93 (0.82-1.05) | 0 | > 0.05 |
- Citation: Song ZQ, Zhou LY. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis. World J Gastroenterol 2016; 22(19): 4766-4775
- URL: https://www.wjgnet.com/1007-9327/full/v22/i19/4766.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i19.4766